Skip navigation

Johnson & Johnson results beat forecasts; Elan share sale helps

(Reuters) - Johnson & Johnson <JNJ.N> on Tuesday reported higher-than-expected quarterly earnings on strong demand for its prescription drugs and medical devices, but a big gain from the sale of a stake in Irish drugmaker Elan Corp <ELN.I> skewed the results.Full story

Earnings Preview: J&J reports 2Q results Tuesday

Johnson & Johnson will discuss sales of key drugs such as blood thinner Xarelto and its ongoing rehabilitation of the ailing consumer health business when it reports second-quarter results before the stock market opens Tuesday. Full story

J&J in $1 billion deal to bolster prostate-cancer focus

(Reuters) - Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand. Full story

Sponsored Links

Articles

New J&J anti-depressant related to 'Special K' party drug

India regulators pull J&J plant license on baby powder concerns

J&J tops estimates on strong prescription drug sales

Analysis: J&J's answer to Botox may escalate war on wrinkles

FDA denies approval to expanded use of J&J/Bayer's Xarelto

Trial plaintiff says J&J hips defective, company says not liable

Jury awards woman $7.76 million in damages for J&J mesh

Jury awards $3.35 million in vaginal mesh case against Johnson & Johnson